AU2008309940B2 - HIV preventive vaccine based on HIV specific antibodies - Google Patents

HIV preventive vaccine based on HIV specific antibodies Download PDF

Info

Publication number
AU2008309940B2
AU2008309940B2 AU2008309940A AU2008309940A AU2008309940B2 AU 2008309940 B2 AU2008309940 B2 AU 2008309940B2 AU 2008309940 A AU2008309940 A AU 2008309940A AU 2008309940 A AU2008309940 A AU 2008309940A AU 2008309940 B2 AU2008309940 B2 AU 2008309940B2
Authority
AU
Australia
Prior art keywords
hiv
peptides
cag
recombinant
ggt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008309940A
Other languages
English (en)
Other versions
AU2008309940A1 (en
Inventor
Elena Yu. Filinova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technologie Integrale Ltd
Original Assignee
Tech Integrale Ltd
Technologie Integrale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tech Integrale Ltd, Technologie Integrale Ltd filed Critical Tech Integrale Ltd
Publication of AU2008309940A1 publication Critical patent/AU2008309940A1/en
Application granted granted Critical
Publication of AU2008309940B2 publication Critical patent/AU2008309940B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008309940A 2007-10-09 2008-10-09 HIV preventive vaccine based on HIV specific antibodies Ceased AU2008309940B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97853607P 2007-10-09 2007-10-09
US60/978,536 2007-10-09
PCT/EP2008/008544 WO2009046984A1 (en) 2007-10-09 2008-10-09 Hiv preventive vaccine based on hiv specific antibodies

Publications (2)

Publication Number Publication Date
AU2008309940A1 AU2008309940A1 (en) 2009-04-16
AU2008309940B2 true AU2008309940B2 (en) 2013-11-14

Family

ID=40342551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008309940A Ceased AU2008309940B2 (en) 2007-10-09 2008-10-09 HIV preventive vaccine based on HIV specific antibodies

Country Status (12)

Country Link
US (1) US20100215695A1 (enExample)
EP (1) EP2205736B1 (enExample)
JP (1) JP2010540674A (enExample)
KR (1) KR20100098597A (enExample)
CN (1) CN101970659A (enExample)
AU (1) AU2008309940B2 (enExample)
BR (1) BRPI0818354A2 (enExample)
CA (1) CA2701948A1 (enExample)
MX (1) MX2010003762A (enExample)
RU (1) RU2505604C2 (enExample)
WO (1) WO2009046984A1 (enExample)
ZA (1) ZA201002445B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422618A1 (en) 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN102190726B (zh) * 2011-03-30 2013-03-27 中国医学科学院病原生物学研究所 一种人源HIV抗体的Fab片段及其编码基因与应用
WO2013040564A2 (en) * 2011-09-17 2013-03-21 Nanjing University Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
US10660951B2 (en) 2012-09-17 2020-05-26 Zhiwei Allen Wu Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
RU2600031C2 (ru) * 2014-11-11 2016-10-20 Публичное акционерное общество "Фармсинтез" Лекарственная форма специфического иммунобиологического лекарственного средства для лечения и профилактики вич инфекции и способ ее получения
EP4276106A3 (en) * 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
US11067583B2 (en) 2016-05-25 2021-07-20 University Of Maryland, Baltimore Methods of making active antibodies from biological fluids
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
EP3641806A4 (en) 2017-06-22 2021-06-23 University of Maryland, Baltimore BROAD NEUTRALIZING ANTIBODIES AGAINST HIV
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
IT202100004160A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Cellula ospite di leishmania
IT202100004172A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Nuova composizione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Choudhry V et al, Virology, 2007, 363(1):79-90 *
Wang X et al, Chinese Science Bulletin, 1999, 44(4):352-356 *
Zhang M-Y et al, Journal of Immunological Methods, 2003, 283(1-2):17-25 *
Zhang M-Y et al, Journal of Immunological Methods, 2006, 317(1-2):21-30 *

Also Published As

Publication number Publication date
RU2505604C2 (ru) 2014-01-27
MX2010003762A (es) 2010-09-10
CN101970659A (zh) 2011-02-09
WO2009046984A1 (en) 2009-04-16
ZA201002445B (en) 2011-03-30
AU2008309940A1 (en) 2009-04-16
JP2010540674A (ja) 2010-12-24
CA2701948A1 (en) 2009-04-16
EP2205736B1 (en) 2014-04-02
US20100215695A1 (en) 2010-08-26
BRPI0818354A2 (pt) 2017-05-16
EP2205736A1 (en) 2010-07-14
RU2010116849A (ru) 2011-11-20
KR20100098597A (ko) 2010-09-08

Similar Documents

Publication Publication Date Title
EP2205736B1 (en) A method for producing an HIV immunogenic composition based on HIV-specific antibodes
RU2539765C2 (ru) ВИЧ ВАКЦИНА, ОСНОВАННАЯ НА НАПРАВЛЕННОСТИ МАКСИМИЗИРОВАННЫХ Gag И Nef НА ДЕНДРИТНЫЕ КЛЕТКИ
Manoutcharian et al. Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis
ES2251734T3 (es) Genes sinteticos de hiv.
AP1282A (en) HIV envelope polypeptides and vaccine.
US8173767B2 (en) Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
CA2258568A1 (en) Vaccines comprising synthetic genes
JP2019126343A (ja) 生体外での効率的な定向増幅用のキメラ抗原受容体及びその適用
JP2018534255A (ja) 転移を低減するための方法および組成物
US8754015B2 (en) Modified phage for displaying post-translationally modified proteins and uses thereof
CA2307503A1 (en) Peptides for use as a vaccine or treatment for hiv infection
CN115851605A (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
JP2018150370A (ja) レンチウイルスの変異ｅｎｖタンパク質及び薬物としてのその使用
US20110212119A1 (en) Methods for making hiv vaccines and related compositions
HK1151554A (en) Hiv preventive vaccine based on hiv specific antibodies
US20170128564A1 (en) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
CN101588813A (zh) 诱导人类免疫缺陷病毒的中和抗体的方法
Josyula Venkata Investigation of B cell and T follicular helper cell responses following priming with immunogens designed to trigger VRC01-class neutralizing antibodies to HIV-1
EP3104884B1 (en) A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection
Gaudet The Isolation of gp41 Specific Monoclonal Antibodies from the Cervical IgA Repertoire of Highly Exposed Persistently Seronegative (HEPS) Commercial Sex Workers from Nairobi, Kenya using Mammalian Cell Display
Regula Fusion glycoproteins of HIV-1 and the Ebola Virus: Structure, function, and inhibition with antibodies
US20100303858A1 (en) Chimeric HIV-1 Glycoproteins and Their Biological Applications
HK1072264B (en) Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv
HK1023371B (en) Compositions and methods for treating viral infections
HK1023371A1 (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired